

**Factor VIII Agents
Prior Authorization Request**

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-855-330-1720.** If you have questions regarding the prior authorization, please contact CVS Caremark at **1-866-814-5506**. For inquiries or questions related to the patient's eligibility, drug copy or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

Patient's Name: _____ Date: _____
Patient's ID: _____ Patient's Date of Birth: _____
Physician's Name: _____
Specialty: _____ NPI#: _____
Physician Office Telephone: _____ Physician Office Fax: _____

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

Additional Demographic Information:

Patient Weight: _____ kg
Patient Height: _____ ft _____ inches

Exception Criteria Questions:

- A. Is the requested product Helixate FS? Yes No, skip to Clinical Criteria Questions
- B. The preferred product for your patient's health plan is Kogenate FS. (Please note: Kogenate FS and Helixate FS are the exact same products with different labels and brand names, which are made by the same manufacturer.)
Can the patient's treatment be switched to Kogenate FS?
 Yes, skip to Clinical Criteria Questions and mark #1 as Kogenate FS No
- C. Given that Kogenate FS and Helixate FS are the same products, is there a clinical reason that the patient must use Helixate FS over Kogenate FS? Yes No
- D. Is this clinical reason documented in the patient's chart? **ACTION REQUIRED: Documentation is required for approval. Provide SPECIFIC AND DETAILED chart documentation including description, date/time, and severity of the clinical reason, dosage and duration of Preferred Product trial, required intervention (if any), and relevant tests or laboratory data (if any) OR MedWatch form of this trial and failure including the adverse reaction.** Yes No

Criteria Questions:

1. What drug is being prescribed?
 Advate Helixate FS
 Hemofil M Kogenate FS
 Monoclate-P Novoeight
 Nuwiq Recombinate
 Xyntha Other _____
2. What is the patient's diagnosis?
 Hemophilia A
 Acquired hemophilia A
 Other _____

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Factor VIII SGM – 1/2017.

CVS Caremark is an independent company that provides pharmacy benefit management services to CareFirst BlueCross BlueShield and CareFirst BlueChoice, Inc. members.

CareFirst BlueCross BlueShield is the shared business name of CareFirst of Maryland, Inc. and Group Hospitalization and Medical Services, Inc. CareFirst BlueCross BlueShield and CareFirst BlueChoice, Inc. are both independent licensees of the Blue Cross and Blue Shield Association. The Blue Cross and Blue Shield Names and Symbols are registered trademarks of the Blue Cross and Blue Shield Association. ® Registered trademark of CareFirst of Maryland, Inc.

3. What is the ICD-10 code? _____

Complete the following section based on the patient's diagnosis.

Section A: Acquired Hemophilia A

4. Does the patient have low levels of spontaneously acquired inhibitors? Yes No

Section B: Hemophilia A

5. Indicate which applies to patient:

- Patient is factor VIII replacement therapy-naive
- Patient is established on factor VIII replacement therapy

6. What is the patient's factor VIII assay level (% activity)? _____ %

ACTION REQUIRED: Attach baseline factor VIII assay level (% activity) for patients naïve to factor VIII replacement therapy. If 5% or less, skip to #9.

7. Has the patient had an insufficient response to desmopressin? *If Yes, skip to #9* Yes No

8. Is there a clinical reason for not trying desmopressin first? Yes No

If Yes, document the reason: _____

9. Does the patient have inhibitors to factor VIII? Yes No *If No, no further questions.*

10. What is the most recent Bethesda (inhibitor) titer (BU): _____ BU/mL Date of result: _____

ACTION REQUIRED: If Yes, please attach laboratory documentation of the most recent Bethesda titer.

11. Will factor VIII be used for immune tolerance induction? Yes No

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.

X _____

Prescriber or Authorized Signature

Date (mm/dd/yy)